Literature DB >> 30576938

Application of a discrete choice experiment approach to support the design of a hepatitis C testing service in primary care.

Andrew Radley1, Marjon van der Pol2, John F Dillon3.   

Abstract

BACKGROUND: Ascertaining the acceptability of healthcare provision to service users is an important factor in promoting service uptake, especially for populations who are reluctant to access care. This study identified the attributes of a Hepatitis C (HCV) testing service for people prescribed Opioid Substitution Therapy (OST) and used their expressed preferences to guide design of a service, using an applied health economics approach.
MATERIALS AND METHODS: Preferences of OST users were elicited using a discrete choice experiment. Important attributes for HCV testing were partly pre-determined by the research question and also identified using literature review and focus groups. Predetermined attributes included choice of provider and financial incentives. Other important attributes were place of testing; travel distance; attitudes and staff undertaking testing; waiting time for test results and incentive payment. The relative importance of defined attributes was assessed in 103 OST users attending 6 pharmacies from Dundee.
RESULTS: OST users preferred testing at their "own pharmacy", by their drug worker, followed by their general practitioner (GP). Use of another pharmacy was the least preferred option. Being treated with dignity and respect was valued most highly, with waiting time for test results and travel distance also important. Financial incentives were not considered important.
CONCLUSIONS: This study provides evidence that OST users prefer testing at their own pharmacy. The addition of a pharmacy to the providers offering HCV testing may increase uptake and support policies to eliminate HCV from our communities. Being treated with dignity and respect was highly valued and this suggests that testing uptake can be increased by developing positive relationships between OST users and test providers. Financial incentives were not found to be important.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical pathways; Community pharmacy; Discrete choice experiment; Hepatitis C

Mesh:

Year:  2018        PMID: 30576938     DOI: 10.1016/j.drugpo.2018.12.008

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  6 in total

1.  The Copenhagen test and treat hepatitis C in a mobile clinic study: a protocol for an intervention study to enhance the HCV cascade of care for people who inject drugs (T'N'T HepC).

Authors:  Jeffrey Victor Lazarus; Anne Øvrehus; Jonas Demant; Louise Krohn-Dehli; Nina Weis
Journal:  BMJ Open       Date:  2020-11-09       Impact factor: 2.692

2.  Meet-Test-Treat for HCV management: patients' and clinicians' preferences in hospital and drug addiction services in Italy.

Authors:  Massimo Andreoni; Nicola Coppola; Antonio Craxì; Stefano Fagiuoli; Ivan Gardini; Alessandra Mangia; Felice Alfonso Nava; Patrizio Pasqualetti
Journal:  BMC Infect Dis       Date:  2022-01-04       Impact factor: 3.090

3.  Randomized clinical trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection.

Authors:  Lewis Beer; Sarah Inglis; Amy Malaguti; Christopher Byrne; Christian Sharkey; Emma Robinson; Kirsty Gillings; Andrew Radley; Adrian Hapca; Brian Stephens; John Dillon
Journal:  J Viral Hepat       Date:  2022-05-26       Impact factor: 3.517

Review 4.  Misalignment of Stakeholder Incentives in the Opioid Crisis.

Authors:  Alireza Boloori; Bengt B Arnetz; Frederi Viens; Taps Maiti; Judith E Arnetz
Journal:  Int J Environ Res Public Health       Date:  2020-10-16       Impact factor: 3.390

5.  Reaching mEthadone users Attending Community pHarmacies with HCV: an international cluster randomised controlled trial protocol (REACH HCV).

Authors:  Christopher Byrne; Andrew Radley; Sarah Karen Inglis; Lewis J Z Beer; Nicki Palmer; Minh Duc Pham; Brendan Healy; Joseph S Doyle; Peter Donnan; John F Dillon
Journal:  BMJ Open       Date:  2020-08-30       Impact factor: 2.692

6.  Real-world outcomes of rapid regional hepatitis C virus treatment scale-up among people who inject drugs in Tayside, Scotland.

Authors:  Christopher J Byrne; Lewis Beer; Sarah K Inglis; Emma Robinson; Andrew Radley; David J Goldberg; Matthew Hickman; Sharon Hutchinson; John F Dillon
Journal:  Aliment Pharmacol Ther       Date:  2021-12-08       Impact factor: 9.524

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.